Matamala Nerea, Martínez Maria Teresa, Lara Beatriz, Pérez Laura, Vázquez Irene, Jimenez Azucena, Barquín Miguel, Ferrarotti Ilaria, Blanco Ignacio, Janciauskiene Sabina, Martinez-Delgado Beatriz
Molecular Genetics Unit, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), Carretera Majadahonda-Pozuelo Km 2,200, 28220, Majadahonda, Madrid, Spain.
Pneumology Department, Hospital 12 de Octubre, Madrid, Spain.
J Transl Med. 2015 Jul 4;13:211. doi: 10.1186/s12967-015-0585-y.
BACKGROUND: SERPINA1 is the gene for alpha-1 antitrypsin (AAT), an acute phase protein with anti-protease and immunoregulatory activities. Mutations in SERPINA1 gene cause AAT deficiency and predispose individuals to early-onset emphysema and liver diseases. Expression of the SERPINA1 gene is regulated by different promoters and alternative splicing events among non-coding exons 1A, 1B and 1C. METHODS: We have developed three quantitative PCR (QT-PCR) assays (1A, 1B and 1C). These assays were applied for the analysis of SERPINA1 alternative transcripts in: (1) 16 human tissues and (2) peripheral blood leukocytes from 33 subjects with AAT mutations and 7 controls. RESULTS: Tissue-specific expression was found for the SERPINA1 transcripts. The 1A transcripts were mainly expressed in leukocytes and lung tissue while those detected with the 1B assay were highly restricted to leukocytes. Only 1B transcripts significantly correlated with serum AAT levels. The 1C transcripts were specifically found in lung, liver, kidney and pancreas. Furthermore, the expression of transcripts was related to AAT genotypes. While deficient variants of AAT had no pronounced effect on the transcript expression, null alleles were associated with significant reduction of different transcripts. CONCLUSIONS: The possibility to discriminate between SERPINA1 alternative splicing products will help us to understand better the regulation of SERPINA1 gene and its association with SERPINA1 mutations-related diseases.
背景:SERPINA1是α-1抗胰蛋白酶(AAT)的基因,AAT是一种具有抗蛋白酶和免疫调节活性的急性期蛋白。SERPINA1基因突变会导致AAT缺乏,并使个体易患早发性肺气肿和肝脏疾病。SERPINA1基因的表达受不同启动子以及非编码外显子1A、1B和1C之间的可变剪接事件调控。 方法:我们开发了三种定量PCR(QT-PCR)检测方法(1A、1B和1C)。这些检测方法用于分析SERPINA1可变转录本:(1)在16种人体组织中;(2)在33名携带AAT突变的受试者和7名对照的外周血白细胞中。 结果:发现SERPINA1转录本具有组织特异性表达。1A转录本主要在白细胞和肺组织中表达,而用1B检测方法检测到的转录本高度局限于白细胞。只有1B转录本与血清AAT水平显著相关。1C转录本在肺、肝、肾和胰腺中特异性表达。此外,转录本的表达与AAT基因型有关。虽然AAT的缺陷变体对转录本表达没有明显影响,但无效等位基因与不同转录本的显著减少有关。 结论:区分SERPINA1可变剪接产物的可能性将有助于我们更好地理解SERPINA1基因的调控及其与SERPINA1突变相关疾病的关联。
J Transl Med. 2015-7-4
Orphanet J Rare Dis. 2014-11-26
Respir Med. 2008-6
Int J Biol Macromol. 2023-6-30
Am J Respir Cell Mol Biol. 2018-6
Proc Natl Acad Sci U S A. 2017-11-6
Am J Respir Crit Care Med. 2024-6-27
Methods Mol Biol. 2024
J Intern Med. 2014-5-13
Nat Rev Mol Cell Biol. 2012-10-17
Am J Respir Cell Mol Biol. 2011-12-8
RNA. 2009-12-28
J Pathol. 2010-1
Curr Protein Pept Sci. 2010-3
Nat Struct Mol Biol. 2009-2